All Stories

  1. In Silico Evaluation of Steroidal Alkaloids as Potential Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitors for Type 2 Diabetes Mellitus
  2. In silico Optimization of Dihydroorotate dehydrogenase Inhibitors for Malaria viaDocking, Molecular Dynamics, and ADMET Evaluation
  3. Study of Class I HDAC-1, -2, and -3 Inhibitors Designed by Bioisosteric Replacement of Zinc Binding Groups and Caps of Traditional Pan Inhibitors: An In Silico Approach
  4. Covalent Inhibitors - An Overview of Design Process, Challenges and Future Directions
  5. Metronidazole—An Old Drug for Structure Optimization and Repurposing
  6. Diaryl Diimidazopyrimidine Derivatives as Potent Inhibitors of Influenza A Virus: Synthesis, Evaluation and Docking Studies
  7. Virtual screening and molecular fingerprinting for in silico designing of potential CCR5 inhibitors targeting HIV therapy
  8. Biosimilar in Cervical Cancer
  9. LAG-3 Inhibitors for the Treatment of Lung Cancer
  10. Structure-based virtual screening of natural compounds against wild and mutant (R1155K, A1156T and D1168A) NS3-4A protease of Hepatitis C virus
  11. Virtual Screening of a Marine Natural Product Database for In Silico Identification of a Potential Acetylcholinesterase Inhibitor
  12. Vanillin based crosslinked films of CMCh-PVA for wound healing application
  13. Ligand-based pharmacophore modeling and QSAR approach to identify potential dengue protease inhibitors
  14. miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease
  15. Pharmacoinformatics based screening of combined synthetic and natural compounds to identify novel and in silico potential Bcl-2 inhibitors
  16. A comprehensive review on acridone based derivatives as future anti-cancer agents and their structure activity relationships
  17. Synthesis and Pharmacological Evaluation of Hexafluoro Functionalized Quinolone Derivatives as Potential Chemotherapeutic Agents
  18. Studies on ligand-based pharmacophore modeling approach in identifying potent future EGFR inhibitors
  19. Computational design of MmpL3 inhibitors for tuberculosis therapy
  20. Development and Characterization of Copper Cross-Linked Freeze-Dried Bioscaffolds for Potential Wound Healing Activity
  21. Supramolecular ternary inclusion complexes of Irbesartan with hydroxypropyl-beta-cyclodextrin
  22. Some metal chelates with Schiff base ligand: synthesis, structure elucidation, thermal behavior, XRD evaluation, antioxidant activity, enzyme inhibition, and molecular docking studies
  23. Enzyme inhibitory function and phytochemical profile of Inula discoidea using in vitro and in silico methods
  24. Ligand-based design approach of potential Bcl-2 inhibitors for cancer chemotherapy
  25. Computational study for identifying promising therapeutic agents of hydroxychloroquine analogues against SARS‐CoV‐2
  26. Screening of natural compounds from Cyperus rotundus Linn against SARS-CoV-2 main protease (Mpro): An integrated computational approach
  27. Structure-based design approach of potential BCL-2 inhibitors for cancer chemotherapy
  28. Experimental and computational insight of the supramolecular complexes of Irbesartan with β-cyclodextrin based nanosponges
  29. Synthesis, Characterization, Enzyme Inhibitory Activity, and Molecular Docking Analysis of a New Series of Thiophene-Based Heterocyclic Compounds
  30. In silico screening of therapeutic potentials from Strychnos nux-vomica against the dimeric main protease (Mpro) structure of SARS-CoV-2
  31. Study of Combinatorial Drug Synergy of Novel Acridone Derivatives With Temozolomide Using in-silico and in-vitro Methods in the Treatment of Drug-Resistant Glioma
  32. In-silico strategies of some selected phytoconstituents from Melissa officinalis as SARS CoV-2 main protease and spike protein (COVID-19) inhibitors
  33. Transition metal complexes of a multidentate Schiff base ligand containing pyridine: synthesis, characterization, enzyme inhibitions, antioxidant properties, and molecular docking studies
  34. Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis
  35. Potential of Probiotics in the Management of Lung Cancer
  36. In silicoidentification of potential inhibitors fromCinnamonagainst main protease and spike glycoprotein of SARS CoV-2
  37. A Critical Review on Anticancer Mechanisms of Natural Flavonoid Puerarin
  38. In silico approach towards the identification of potential inhibitors from Curcuma amada Roxb against H. pylori: ADMET screening and molecular docking studies
  39. Synthesis of 3, 4-dihydropyrimidin-2(1H)-one derivatives and evaluation of their antibacterial activity
  40. Design Potent Telomerase Inhibitors Using Structure Based Approaches
  41. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy
  42. Reappraisal of FDA approved drugs against Alzheimer’s disease based on differential gene expression and protein interaction network analysis: an in silico approach
  43. Hit identification and drug repositioning of potential non-nucleoside reverse transcriptase inhibitors by structure-based approach using computational tools (part II)
  44. Improved treatment efficacy of risedronate functionalized chitosan nanoparticles in osteoporosis: formulation development, in vivo, and molecular modelling studies
  45. Design of metronidazole derivatives and flavonoids as potential non-nucleoside reverse transcriptase inhibitors using combined ligand- and structure-based approaches
  46. Ligand based design and synthesis of pyrazole based derivatives as selective COX-2 inhibitors
  47. Synthesis of novel gefitinib‐based derivatives and their anticancer activity
  48. An update on Drug Repurposing: Re-written saga of the drug’s fate
  49. Role of Natural Products in Glaucoma Management
  50. Host-guest interaction study of Efavirenz with hydroxypropyl‑β‑cyclodextrin and l‑arginine by computational simulation studies: Preparation and characterization of supramolecular complexes
  51. Study on effect of L-arginine on solubility and dissolution of Zaltoprofen: Preparation and characterization of binary and ternary cyclodextrin inclusion complexes
  52. Phytochemicals and PI3K Inhibitors in Cancer—An Insight
  53. Acridone-pyrimidine hybrids- design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies
  54. Complexation of phytochemicals with cyclodextrin derivatives – An insight
  55. Design, synthesis, biological evaluation, molecular docking and QSAR studies of 2,4-dimethylacridones as anticancer agents
  56. Inclusion Complexes of Nateglinide with HP–β–CD and L-Arginine for Solubility and Dissolution Enhancement: Preparation, Characterization, and Molecular Docking Study
  57. Inclusion Complexation of Etodolac with Hydroxypropyl-beta-cyclodextrin and Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies
  58. Current Overview on the Usage of Poly(ADP-ribose)polymerase (PARP) Inhibitors in Treating Cancer
  59. Identification and Usage of Fluorescent Probes as Nanoparticle Contrast Agents in Detecting Cancer